Structure-activity models of oral clearance, cytotoxicity, and LD50: a screen for promising anticancer compounds

John C Boik1, Robert A Newman

  • 1Department of Experimental Therapeutics, University of Texas M, D, Anderson Cancer Center, 8000 El Rio, Houston, TX 77054, USA. jcboik@stanford.edu

BMC Pharmacology
|June 17, 2008
PubMed
Abstract